For first-line treatment of SCLC, the addition of atezolizumab, an anti-programmed death ligand 1 (PD-L1) antibody, to carboplatin and etoposide in the phase 3 IMpower133 trial3 significantly improved median survival from 10.3 to 12.3 months; however, only 12.6% of patients remained progression-free at 1 year. The gene discussed is CD274; the disease is small cell lung carcinoma.